{
  "id": "mhgap#risk_safety_fc5ebe12",
  "title_en": "General — Risk Safety",
  "title_vi": "General — Nguy cơ An toàn",
  "text_en": "Executive summary TABLE 1. (continued) Summary of recommendations Module and Recommendation recommendation Strength of the recommendation and certainty of the evidence number PSY5 (update) 5.1 Oral antipsychotic medicines – namely aripiprazole, olanzapine, paliperidone, quetiapine, risperidone – should be considered under specialist supervision for adolescents with psychotic disorders (including schizophrenia), carefully balancing effectiveness, side-effects and individual preference. Conditional recommendation. Low certainty of evidence. 5.2 Clozapine should be considered for adolescents with a treatment-resistant psychotic disorder (including schizophrenia) under specialist supervision, carefully balancing effectiveness, side-effects and individual preference. Conditional recommendation. Low certainty of evidence. PSY6 (update) Psychotropic medicines (antipsychotic medicines, namely aripiprazole, olanzapine, quetiapine, risperidone; and mood stabilizers, namely lithium) should be considered under specialist supervision for adolescents with bipolar disorder (current episode manic), carefully balancing effectiveness, side-effects and individual preference. Conditional recommendation. Very low certainty of evidence. PSY7 (update) 7.1 Oral antipsychotic medicines (namely aripiprazole, haloperidol, olanzapine, paliperidone or quetiapine) or mood stabilizers (namely carbamazepine, lithium, valproic acid [sodium valproate]) should be offered to adults with bipolar disorder (current episode mania), carefully balancing effectiveness, side-effects and individual preference. Strong recommendation. Low certainty of evidence. 7.2 Valproic acid (sodium valproate) should not be used in women and girls of childbearing potential, owing to the high risk of birth defects and neurodevelopmental disorders in babies in utero. Strong recommendation. Low certainty of evidence. PSY8 (update) 8.1 Mood stabilizers (namely carbamazepine, lithium, valproic acid [sodium valproate]) or oral antipsychotic medicines (namely aripiprazole, olanzapine, quetiapine) should be considered for maintenance treatment for adults with bipolar disorder in remission, carefully balancing effectiveness, side-effects and individual preference. Conditional recommendation. Low certainty of evidence. 8.2 Valproic acid (sodium valproate) should not be used in women and girls of childbearing potential with bipolar disorder in remission, owing to the high risk of birth defects and neurodevelopmental disorders in babies in utero. Strong recommendation. Low certainty of evidence. xxix Mental Health Gap Action Programme (mhGAP) guideline",
  "gloss_vi": "Executive summary table 1. (continued) summary of recommendations module and recommendation recommendation strength of the recommendation and certainty of the evidence number psy5 (update) 5.1 oral antipsychotic medicine...",
  "source": "WHO mhGAP-IG 2023",
  "url": "https://www.who.int/",
  "lang": "en",
  "axes": {
    "type": [
      "clinical"
    ],
    "condition": [
      "General"
    ],
    "clinical_section": [
      "risk_safety",
      "referral",
      "management"
    ],
    "life_topics": [],
    "advice_section": [],
    "audience": [],
    "risk_band": "low"
  },
  "index_text": "General — Risk Safety General — Nguy cơ An toàn Executive summary TABLE 1. (continued) Summary of recommendations Module and Recommendation recommendation Strength of the recommendation and certainty of the evidence number PSY5 (update) 5.1 Oral antipsychotic medicines – namely aripiprazole, olanzapine, paliperidone, quetiapine, risperidone – should be considered under specialist supervision for adolescents with psychotic disorders (including schizophrenia), carefully balancing effectiveness, side-effects and individual preference. Conditional recommendation. Low certainty of evidence. 5.2 Clozapine should be considered for adolescents with a treatment-resistant psychotic disorder (including schizophrenia) under specialist supervision, carefully balancing effectiveness, side-effects and individual preference. Conditional recommendation. Low certainty of evidence. PSY6 (update) Psychotropic medicines (antipsychotic medicines, namely aripiprazole, olanzapine, quetiapine, risperidone; and mood stabilizers, namely lithium) should be considered under specialist supervision for adolescents with bipolar disorder (current episode manic), carefully balancing effectiveness, side-effects and individual preference. Conditional recommendation. Very low certainty of evidence. PSY7 (update) 7.1 Oral antipsychotic medicines (namely aripiprazole, haloperidol, olanzapine, paliperidone or quetiapine) or mood stabilizers (namely carbamazepine, lithium, valproic acid [sodium valproate]) should be offered to adults with bipolar disorder (current episode mania), carefully balancing effectiveness, side-effects and individual preference. Strong recommendation. Low certainty of evidence. 7.2 Valproic acid (sodium valproate) should not be used in women and girls of childbearing potential, owing to the high risk of birth defects and neurodevelopmental disorders in babies in utero. Strong recommendation. Low certainty of evidence. PSY8 (update) 8.1 Mood stabilizers (namely carbamazepine, lithium, valproic acid [sodium valproate]) or oral antipsychotic medicines (namely aripiprazole, olanzapine, quetiapine) should be considered for maintenance treatment for adults with bipolar disorder in remission, carefully balancing effectiveness, side-effects and individual preference. Conditional recommendation. Low certainty of evidence. 8.2 Valproic acid (sodium valproate) should not be used in women and girls of childbearing potential with bipolar disorder in remission, owing to the high risk of birth defects and neurodevelopmental disorders in babies in utero. Strong recommendation. Low certainty of evidence. xxix Mental Health Gap Action Programme (mhGAP) guideline Executive summary table 1. (continued) summary of recommendations module and recommendation recommendation strength of the recommendation and certainty of the evidence number psy5 (update) 5.1 oral antipsychotic medicine..."
}